"The thing that the space needs is a company making $100 million a year of revenue," Science Corp. CEO Max Hodak said.

The four-year-old firm's latest fund is 60% larger than its second vehicle announced 18 months ago.

The de-extinction startup is looking to double or triple its previous valuation, according to the report.

One period tracker app tested by Mozilla was 'squeaky clean,' while another app was seen sharing users' health data with an analytics company, underscoring vast differences in user privacy among these apps.

Neko Health has developed proprietary body-scanning technology, which it couples with bloodwork, to assess a person's health.

The funding discussions point to investor interest in applying AI to make breakthroughs in life sciences.

When we last sat down with Jobs at TechCrunch Disrupt nearly three years ago, his firm Yosemite was brand new and biotech was still reeling from its post-pandemic crash. Now, the venture outfit has a team of 17; a cluster of blockbuster drugs are all losing patent protection in roughly the same window, creating all kinds of new opportunities; and AI has gone from a curiosity to, in Jobs' words, a huge part of what Yosemite does. "I didn't expect Yosemite to be moving this fast," he said.